Clinical Trial Update: Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating safety and immunogenicity of a live attenuated varicella vaccine in healthy individuals aged 13 and older.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Varicella

Drugs mentioned

• Varicella vaccine (live attenuated vaccine) - Sinovac (Dalian) Vaccine Technology Co., Ltd. formulation

Snippet

Sponsor: Sinovac (Dalian) Vaccine Technology Co., Ltd. | Conditions: Varicella | Phase 3 | Status: ENROLLING_BY_INVITATION